Mild Cognitive Impairment Treatment Market Size of the 7MM was ~USD 2,836 million in 2023, and is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Mild Cognitive Impairment Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Mild Cognitive Impairment, historical and forecasted epidemiology as well as the Mild Cognitive Impairment therapeutics market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

To Know in detail about the Mild Cognitive Impairment market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mild Cognitive Impairment Market Forecast @ https://www.delveinsight.com/sample-request/mild-cognitive-impairment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Mild Cognitive Impairment Market Report
• In June 2025, Sage Therapeutics announced a study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
• In June 2025, UCB Biopharma SRL conducted a study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's Disease (AD).
• In June 2025, Eisai Inc. organized a study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of E2814 on microtubule binding region (MTBR)-tau species in cerebrospinal fluid (CSF) in participants with DIAD.
• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Parkinson's disease in the US were nearly 1,211 thousand in 2023.
• Among European countries, Germany had the highest diagnosed prevalent cases of Alzheimer's disease with ~1,491 thousand cases, followed by France, which had diagnosed prevalent population of ~1,170 thousand in 2023. On the other hand, the UK had the lowest prevalent population (620 thousand cases).
• In Japan, approximately 2,730 thousand diagnosed cases of Mild Cognitive Impairment were identified, with around 103 thousand cases attributed to Mild Cognitive Impairment due to Parkinson's disease and 2,627 thousand cases due to Alzheimer's. Projections suggest that by 2034, the prevalence of Alzheimer's-related Mild Cognitive Impairment will continue to grow and exceed that of Parkinson's-related Mild Cognitive Impairment, highlighting a trend that underscores the increasing impact of Alzheimer's on the aging population.
• DelveInsight's analysis shows that, among the 7MM, the US accounted highest for the total diagnosed prevalent cases of Mild Cognitive Impairment. There were nearly 4,222 thousand diagnosed prevalent cases of Mild Cognitive Impairment in the US in 2023. Projections indicate that the UK is expected to continue leading in these figures by 2034.
• The leading Mild Cognitive Impairment Companies such as FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others
• Promising Mild Cognitive Impairment Pipeline Therapies such as T-817MA, NYX-458, Aptinyx, T-817MA, Aricept (donepezil hydrochloride), CX516, AL-208, CST-2032, ladostigil hemitartrate, AZD5213, SAGE-718, fesoterodine, MMH-MAP, Donanemab, Flutemetamol (18F) Injection, EVP-0962, and others.

Get a Free sample for the Mild Cognitive Impairment Market Report @ https://www.delveinsight.com/sample-request/mild-cognitive-impairment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Mild Cognitive Impairment Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of Parkinson's Disease
• Total Diagnosed Prevalent Cases of Alzheimer's Disease
• Total Diagnosed Prevalent Cases

Download the report to understand which factors are driving Mild Cognitive Impairment epidemiology trends @ Mild Cognitive Impairment Epidemiology Forecast @ https://www.delveinsight.com/sample-request/mild-cognitive-impairment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Mild Cognitive Impairment Marketed Drugs
• LEQEMBI (lecanemab): Biogen Inc./Eisai Co., Ltd.
LEQEMBI, an FDA-approved treatment for Alzheimer's, specifically targets patients in the Mild Cognitive Impairment or mild dementia stages. Developed as a humanized IgG1 monoclonal antibody, LEQEMBI addresses amyloid ß (Aß) pathology by reducing both soluble and insoluble forms of Aß to slow disease progression. With ongoing prescription expansion, the focus includes customized facility information on the drug, reimbursement support, and system efficiency enhancements. Approved by regulatory bodies in Great Britain (August 2024) and Japan (September 2023), LEQEMBI marks a significant milestone as the first approved therapy in Europe to target an Alzheimer's-related pathology directly.

• KISUNLA (Donanemab): Eli Lilly and Company
KISUNLA (donanemab-azbt), developed by Eli Lilly, targets amyloid plaques in patients with Mild Cognitive Impairment or early symptomatic Alzheimer's disease confirmed by amyloid pathology. This humanized IgG1 monoclonal antibody addresses amyloid ß accumulation-a key contributor to Alzheimer's by focusing on insoluble N-truncated pyroglutamate amyloid beta plaques. Administered intravenously every four weeks, KISUNLA's structured dosing regimen was informed by Phase III TRAILBLAZER-ALZ 2 trial data, supporting approvals in the US (July 2024) and Japan (September 2024). Unique to KISUNLA is the potential to halt treatment once plaques clear, which may optimize efficacy and lower treatment costs.

Emerging Mild Cognitive Impairment Drugs
• Valiltramiprosate (ALZ-801): Alzheon Inc.
ALZ-801 (valiltramiprosate) is an oral, small-molecule drug designed to fully inhibit the formation of neurotoxic amyloid oligomers linked to Alzheimer's disease progression. As a valine-conjugated prodrug of tramiprosate, ALZ-801 is converted in vivo to homotaurine, enhancing absorption and extending plasma stability compared to tramiprosate. Both ALZ-801 and tramiprosate are metabolized into 3-sulfopropanoic acid (3-SPA), a naturally occurring brain substance that impedes Aß42 aggregation. ALZ-801's improved pharmacokinetic profile minimizes gastrointestinal issues and maintains consistent blood levels, with Phase I data supporting its tolerability. Now in Phase III, ALZ-801 is investigated as a disease-modifying therapy for Mild Cognitive Impairment.

• Mirodenafil (AR1001): AriBio Co., Ltd.
AR1001 is an orally administered, blood-brain barrier-penetrating small molecule with a polypharmacological profile targeting neurodegenerative diseases. It works primarily by selectively inhibiting phosphodiesterase 5 (PDE5), aiming to treat conditions such as Alzheimer's disease, vascular dementia, and Lewy body dementia. Following promising Phase II results for mild-to-moderate Alzheimer's in the US, AriBio is advancing AR1001 into Phase III trials for early Alzheimer's, targeting patients with Mild Cognitive Impairment and mild dementia. Phase III trials are set in the US and Europe. In June 2024, AriBio partnered with Kentucky Clinical Trial Laboratory (KCTL) for Alzheimer's diagnostics, utilizing FujireBio's Lumipulse system.

• Hydromethylthionine Mesylate (HMTM)/TRx0237: TauRx Therapeutics
TauRx Therapeutics' TRx0237, also known as Hydromethylthionine Mesylate (HMTM), is an orally active second-generation Tau protein Aggregation Inhibitor (TAI) targeting tau protein aggregation, which is associated with neurofibrillary tangles in Alzheimer's disease and other neurodegenerative disorders. Tau tangles are implicated in dementia as they form from misfolded tau proteins, leading to neuronal death. TRx0237 is a stabilized, reduced version of methylthioninium chloride (MTC), enhancing absorption, bioavailability, and tolerability. The drug has successfully completed three Phase III trials-two focused on Alzheimer's disease and one on behavioral variant frontotemporal dementia (bvFTD).

Discover more about therapies set to grab major Mild Cognitive Impairment market share @ Mild Cognitive Impairment Treatment Market- https://www.delveinsight.com/sample-request/mild-cognitive-impairment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Mild Cognitive Impairment Market Outlook
Mild Cognitive Impairment presents as cognitive decline that exceeds typical age-related changes but does not significantly disrupt daily living. Its progression to dementia, particularly Alzheimer's disease, underscores the importance of early detection and intervention. Treatment strategies focus on modifiable risk factors, such as dietary habits, hypertension, and physical activity. While pharmacological options like cholinesterase inhibitors (ChEIs) and memantine may be employed in Alzheimer's-related cases, non-pharmacological interventions including cognitive training, exercise, and lifestyle changes are vital for managing Mild Cognitive Impairment.

Mild Cognitive Impairment Treatment Market
Mild Cognitive Impairment treatment necessitates personalized management approaches, particularly in patients with comorbid conditions. Although ChEIs are frequently prescribed for Alzheimer's, their efficacy in Mild Cognitive Impairment remains unproven, leading to potential deprescribing recommendations. Established treatments like donepezil, rivastigmine, and galantamine show modest and temporary benefits, while memantine proves effective in moderate to severe cases. With a growing focus on advanced treatment options, the market for Mild Cognitive Impairment is expanding, highlighting opportunities for innovation and investment in new therapies and technologies. The Mild Cognitive Impairment market is poised for transformation with the anticipated introduction of therapies like Valiltramiprosate, Mirodenafil, Hydromethylthionine mesylate (HMTM), and others. The approval of these therapies could significantly impact market dynamics, although their success rates remain uncertain.

To know more about Mild Cognitive Impairment companies working in the treatment market, visit @ Mild Cognitive Impairment Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/mild-cognitive-impairment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Mild Cognitive Impairment Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Mild Cognitive Impairment Companies- FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others
• Mild Cognitive Impairment Pipeline Therapies- T-817MA, NYX-458, Aptinyx, T-817MA, Aricept (donepezil hydrochloride), CX516, AL-208, CST-2032, ladostigil hemitartrate, AZD5213, SAGE-718, fesoterodine, MMH-MAP, Donanemab, Flutemetamol (18F) Injection, EVP-0962, and others.
• Mild Cognitive Impairment Market Dynamics: Mild Cognitive Impairment Market Drivers and Barriers
• Mild Cognitive Impairment Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Mild Cognitive Impairment Drugs in development @ Mild Cognitive Impairment Clinical Trials Assessment- https://www.delveinsight.com/sample-request/mild-cognitive-impairment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Report Introduction
3. Mild Cognitive Impairment Market Overview at a Glance
4. Methodology of Mild Cognitive Impairment Epidemiology and Market
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Mild Cognitive Impairment Patient Journey
9. Mild Cognitive Impairment Epidemiology and Patient Population
10. Mild Cognitive Impairment Marketed Drugs
11. Emerging Mild Cognitive Impairment Drug Profiles
12. Mild Cognitive Impairment: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Mild Cognitive Impairment Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

List of Top Selling Market Research Reports in 2025

radial artery compression device market- https://www.delveinsight.com/report-store/transradial-access-products-market
vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
cone rod dystrophy market- https://www.delveinsight.com/report-store/cone-rod-dystrophy-market
opioid-related disorders market- https://www.delveinsight.com/report-store/opioid-related-disorders-market
adeno associated viruses aav gene therapy market- https://www.delveinsight.com/report-store/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight
cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
methicillin-resistant staphylococcus aureus infection market- https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-market
pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
atopic dermatitis market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
cardiogenic shock market- https://www.delveinsight.com/report-store/early-cardiogenic-shock-cs-market
chemotherapy induced neutropenia market- https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
CXCR inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
friedreich's ataxia market- https://www.delveinsight.com/report-store/friedreichs-ataxia-market
herpes labialis market- https://www.delveinsight.com/report-store/herpes-labialis-market
herpes zoster market- https://www.delveinsight.com/report-store/herpes-zoster-market
somatotropin deficiency market- https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market
spinal trauma devices market- https://www.delveinsight.com/report-store/trauma-devices-market
tcr therapy market- https://www.delveinsight.com/report-store/tcr-therapy-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
atherosclerosis market- https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
chronic heart failure market- https://www.delveinsight.com/report-store/heart-failure-market
chronic venous ulceration market- https://www.delveinsight.com/report-store/chronic-venous-ulceration-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
hypertrophic cardiomyopathy market- https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market
langerhans cell histiocytosis market- https://www.delveinsight.com/report-store/langerhans-cell-histiocytosis-market
liver fibrosis market- https://www.delveinsight.com/report-store/liver-fibrosis-market
membranous nephropathy market- https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
plaque modification devices market- https://www.delveinsight.com/report-store/plaque-modification-devices-market
primary ciliary dyskinesia market- https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-market
psoriasis vulgaris market- https://www.delveinsight.com/report-store/psoriasis-vulgaris-market
radiodermatitis market- https://www.delveinsight.com/report-store/radiation-dermatitis-market
ranibizumab biosimilars market- https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
seasonal allergic rhinitis market- https://www.delveinsight.com/report-store/allergic-rhinitis-market
sly syndrome market- https://www.delveinsight.com/report-store/sly-syndrome-market
social anxiety disorder market- https://www.delveinsight.com/report-store/social-anxiety-disorder-market
soft tissue sarcoma with lung metastasis market- https://www.delveinsight.com/report-store/soft-tissue-sarcoma-with-lung-metastases-market
surgical bleeding market- https://www.delveinsight.com/report-store/surgical-bleeding-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.